To determine whether or not FXR could be an effective therapeutic target for pancreatic cancer, the effect of FXR siRNA on cell proliferation was examined in MIA-PaCa2 and PANC-1 cells. This evidence concerns the gene NR1H4 and familial pancreatic carcinoma.